The assay will screen compounds to modulate the activity of the recently discovered KCNH2 3.1 potassium channel, which is increased in the brains of patients with schizophrenia. The assay will use a high throughput thallium flux assay to find potential antipsychotic drug candidates without cardiac side effects. The wild type KCNH2 channel will also be screened to help identify selective modulators of the KCNH2 3.1 channel. The resulting compounds will be validated in electrophysiology experiments and tested in animal models to assess their effects on memory and other aspects of animal physiology linked with psychosis. Is the molecule effective to this assay?